drugset / Trial / NCT05636228
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Phase 2
Completed
93 enrolled
Invirsa, Inc.
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.
Timeline
- Start
- 2023-06-09
- Primary completion
- 2024-08-22
- Completion
- 2024-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INV-102 | Unknown | 0.7 % | Topical |